← 홈

전체 프로그램

ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 217개
CGTSHOTFDACuratedFDABiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 92%임상시험 66상태 APPROVED
CGTAHOTFDACuratedFDABiologicNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 82.3%임상시험 48상태 APPROVED
CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 77.3%임상시험 96상태 RECRUITING
CGTBBiologicBioceltech Therapeutics, Ltd.Phase 1

CD19 CAR T cells (CD19 CAR T cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
효능 ORR 88%임상시험 73상태 RECRUITING
CGTBiologicJuventas Cell Therapy Ltd.Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

Multi-Drug Resistant Nephrotic Syndrome; CAR-T Cell Therapy · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
효능 ORR 94%임상시험 68상태 ACTIVE
CGTBiologicJuventas Cell Therapy Ltd.Phase 2

CD19 CAR-T (CD19 CAR-T)

B-cell Malignancy; B-cell Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 88%임상시험 66상태 ACTIVE
CGTBiologicSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
효능 ORR 94%임상시험 60상태 ACTIVE
CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicAbClonvedotin-containing regimens…Phase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 38%임상시험 59상태 RECRUITING
CGTBiologicJiangsu Topcel-KH Pharmaceutica…Phase 2

CD19 CAR T Arm (CD19 CAR T Arm)

Scleroderma, Systemic · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 16.7%임상시험 56상태 RECRUITING
CGTBiologicYake Biotechnology Ltd.Phase 1

CD19/CD22 CAR T-Cells (CD19/CD22 CAR T-Cells)

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
임상시험 54상태 RECRUITING
CGTBiologicHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicCRISPR Therapeutics AGPhase 2

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 25%임상시험 53상태 ACTIVE
ADCBBiologicADC TherapeuticsthatPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 94.1%임상시험 48상태 RECRUITING
CGTBiologicjiuwei cuiPhase 1

CD19-targeted CART cells (CD19-targeted CART cells)

Leukemia, B-Cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 39상태 ACTIVE
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

CD19+22 CAR-T cells (CD19+22 CAR-T cells)

Acute Lymphobkastic Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 1%임상시험 33상태 RECRUITING
CGTBiologicRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 0%임상시험 32상태 ACTIVE
CGTBiologicVinmec Research Institute of St…Phase 1

Autologous CD19-Targeted CAR-T Cells (Autologous CD19-Targeted CAR-T Cells)

Refractory Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 92%임상시험 31상태 RECRUITING
CGTBiologicChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING

1 / 11 페이지

← 이전다음 →